ReviewDeutsches Arzteblatt international2015
The Diagnosis and Treatment of Bronchopulmonary Carcinoid.
Review in Deutsches Arzteblatt international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Atypical Behavior in a Typical Carcinoid: When Minimal Proliferation Meets Lympho-Vascular Invasion-A Case Report.Thoracic cancer · 2026Article
- Enhancing Diagnostic Pathways for Bronchopulmonary Neuroendocrine Tumors: Assessment of the South Wales Neuroendocrine Tumor Service Transformation.Thoracic cancer · 2026Article
- Vertebral Metastasis in a Bronchial Carcinoid: A Rare Case Report with More than 3-Year Follow-Up and Review of the Literature.Diagnostics (Basel, Switzerland) · 2025Article
- Differentiating lung neuroendocrine neoplasms from tumor-like infection using CT in patients with ectopic ACTH syndrome.Insights into imaging · 2024Article
- The presentation pattern and surgical strategies in bronchopulmonary carcinoid tumors: a multicenter experience in a low-income country.Frontiers in surgery · 2024Article
- Prognostic nomogram and epidemiological analysis for lung atypical carcinoid: A SEER database and external validation study.Cancer medicine · 2024Article
- Complete Regression of Endobronchial Carcinoid Tumor after an Endoscopic Biopsy.Internal medicine (Tokyo, Japan) · 2023Article
- Prognostic factors for pulmonary carcinoid with positive lymph node after surgical resection: a SEER database study.General thoracic and cardiovascular surgery · 2023Article
- Review
- Article
- Bronchoscopic diagnosis and treatment of endobronchial carcinoid: case report and review of the literature.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Bronchial Carcinoid Tumors with Massive Osseous Metaplasia: A Case Report and Review of the Literature.Turk patoloji dergisi · 2020Review
- Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.Neuroendocrinology · 2020Article
- Bronchial carcinoid tumor: A case report.International journal of surgery case reports · 2020Article
- [Pulmonary carcinoids and carcinoids of the small intestine].Der Radiologe · 2019Review
- [Surgical Resection and Prognosis of Bronchopulmonary Carcinoid].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Article
- Spontaneous Partial Regression of a Carcinoid Tumor: Radiology May Not Capture the Real Picture.Turkish thoracic journal · 2019Article
- Complete lung collapse in a young adolescent.African journal of thoracic and critical care medicine · 2018Article
- Management of pulmonary neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2017Review
- Superior mediastinal typical carcinoid detected by 99mTc-MIBI SPECT/CT imaging: A case report.Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe spectrum of primary neuroendocrine tumors of the lungs ranges from typical carcinoid tumors, which are relatively benign, to highly aggressive small-cell carcinoma. In this review, we summarize the treatment of bronchopulmonary carcinoid, a disease with an incidence of 0.5 per 100,000 persons per year in Western countries.
methodWe selectively searched the PubMed database for scientific evidence on the treatment of bronchopulmonary carcinoid, considering only articles published up to February 2015. We also performed a survival analysis of 84 patients with this disease who underwent interdisciplinary treatment at the University of Freiburg Medical Center.
resultsCarcinoid tumors account for less than 1% of all lung tumors. They manifest themselves clinically with cough (35%), hemoptysis (25%), and/or bronchial obstruction (40%), depending on their location, size, and pattern of growth. 30% of patients are asymptomatic, and less than 1% have hormone-associated symptoms. Typical and atypical carcinoid tumors are distinguished on a histological basis; the histologic differential diagnosis also includes large-cell neuroendocrine tumors and small-cell carcinoma of the lung. 80% of patients who undergo resection of typical carcinoid tumors survive at least 10 years. Atypical carcinoid tumors recur more commonly than typical ones. If the mediastinal lymph nodes are involved, adjuvant treatment should be considered.
conclusionBecause of their rarity, the treatment of bronchopulmonary carcinoid tumors presents an interdisciplinary challenge. Surgical resection, the treatment of choice for local carcinoid tumors, generally leads to long-term survival. The existing registers should be made more comprehensive so that the treatment of this disease can be better in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.